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Fractional Flow Reserve: Overview and Implications for Clinical
Decision Making
WILLIAM KONG-TO HAU
From Department of Physiology and Institute of Cardiovascular Science and Medicine, Faculty of Medicine,
The University of Hong Kong, Hong Kong
HAU: Fractional Flow Reserve: Overview and Implications for Clinical Decision Making. Pressure derived
fractional flow reserve (FFR) is a well-validated index to assess functional significance of stenosis severity that has
evolved from a physiological index to a clinical tool. The objective of this paper is to provide a short overview of the
theoretical and physiological background of this physiological assessment technique and to focus on its clinical
applicability in both diagnostic and interventional procedures. (J HK Coll Cardiol 2003;11:83-89)
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Introduction
One of the main limitations of coronary
angiography is the inability to determine the
physiological significance of a stenosis on coronary
blood flow. As a result, physiological assessment
techniques have been introduced to determine the
functional significance of coronary lesions that may
require revascularization. With recent technology
advances in interventional cardiology, miniaturized
pressure sensing guide wires for the assessment of distal
coronary pressure are now available.1 Also with the
development of the fractional flow reserve (FFR) index

have offered an easy and convenient method for
measuring the physiological impact of a coronary
stenosis.2 FFR is defined as the ratio of the maximal
blood flow achievable in a stenotic vessel to the normal
maximal flow in the same vessel, which represents the
fraction of maximum flow that can still be maintained
in spite of the presence of the stenosis. FFR is an
important index in the diagnosis of myocardial ischemia
and the decision for coronary intervention. It is exactly
this index which indicates to what degree a patient is
limited by the coronary stenosis.
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FFR has been extensively studied and clinically
validated.2-5 The basis of the concept is illustrated in
Figure 1. Under conditions of maximum arteriolar
vasodilation, myocardial resistance of that system will
be minimal, and thus blood flow is proportional to
driving pressure. If there is no stenosis in the artery,
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Maximum myocardial flow in the
presence of a coronary stenosis
FFR =
Normal maximum flow
Or
P d - Pv
FFR =
Pa - Pv

Figure 1. A simplified schematic illustration of the coronary
artery and its dependent myocardial vascular bed to explain
the concept of FFR. At maximum hyperemia, myocardial
perfusion pressure would be 100 mmHg if the artery is normal
with no stenosis. However, if there is a stenosis, the perfusion
pressure will drop to 60 mmHg. Therefore the ratio of the
maximal blood flow achievable in a stenotic vessel to the
normal maximal flow in the same vessel is (60-0)/(100-0),
which implies the maximum amount of blood flow to the
myocardium in this stenotic artery is only 60% of normal
maximum flow if the artery is free of any disease, and by
definition FFR of the myocardium is 0.6. Where Pa, Pd and Pv
represent mean aortic, distal coronary and central venous
pressures obtained at maximum coronary hyperemia.

driving pressure over the myocardium will be 100
mmHg. However, if there is a stenosis, it will result in
a gradient of 40 mmHg at maximum vasodilation. The
overall maximum driving pressure has fallen to only
60 mmHg, which implies the maximum amount of blood
flow to the myocardium in this stenotic artery is only
60% of normal maximum flow if the artery is free of
any disease, and by definition FFR of the myocardium
is 0.6. In other words, FFR represents the fraction of
maximum flow that can be still maintained in spite of
the presence of the stenosis, and can be expressed by
the following equation:
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≅

Pd
Pa

Where Pa, Pd and Pv represent mean aortic, distal
coronary and central venous pressures obtained at
maximum coronary hyperemia. Because central venous
pressure usually is close to zero, Pv can be neglected.
As a result, an accurate estimate of FFR can be derived
from the ratio of mean distal coronary artery pressure
to aortic pressure during maximal coronary hyperemia.
Pa is measured routinely by the coronary guiding
catheter, the only things needed to measure FFR are a
pressure guide wire enabling reliable distal coronary
pressure recording and a maximum hyperemic stimulus.
The standard means for inducing hyperemia is by the
administration of adenosine.
FFR is a lesion specific index of epicardial
stenosis severity. The theoretical unequivocal normal
value for FFR is 1.0;2 a value of 0.75 reliably identifies
stenosis associated with inducible ischemia.6 As a
normal reference vessel is not required, FFR can be used
in multivessel disease.2 The measurement of FFR is
highly reproducible and is independent of changes in
hemodynamics or myocardial contractility.7

Coronary Pressure Measurement
At present, two FDA-approved pressure guide
wire systems are available: Pressure Analyzer (RADI
Medical Systems, Sweden) and WaveMap (JOMED
AB, Sweden). Both are micromanometer-tipped
0.014-inch guide wires with a pressure sensor located
just proximal to the junction between the radiopaque
distal tip and the nonradiopaque part of the wire.
Their handling characteristics are very similar to
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conventional angioplasty guide wires and are
compatible with monorail balloon catheters. The
proximal end of each wire is disconnectable and is
connected to a special rotary connector. The rotary
connector is then further connected into an interface
box that will either display the distal coronary
pressure itself or convert the signal into pressure
displayed on the ordinary pressure monitoring system
in the cardiac catheterization laboratory. The pressure
monitoring guide wire is first zeroed and advanced
up to the tip of the guiding catheter. At this location,
the aortic pressure and the pressure obtained from
the pressure monitoring guide wire should be
identical, otherwise these two pressure signals need
to be normalized before carrying out any further
procedures. Thereafter, the pressure monitoring guide
wire is then advanced and positioned distal to the
lesion. The pressure gradient is recorded at baseline
and after administering a stimulus, FFR is then
automatically determined by the pressure interface
box.

Pharmacologic Hyperemic Stimuli
Achievement of maximum hyperemia is needed
in order to obtain a meaningful FFR measurement,
otherwise the actual severity of the stenosis will be
underestimated, and thus administration of a
pharmacological vasodilator either as intracoronary (IC)
bolus or as a continuous intravenous (IV) infusion is
needed for coronary pressure measurement. Several
pharmacological vasodilator agents have been used,
including adenosine 5'- triphosphate (ATP), adenosine,
papaverine and dobutamine (Table 1). Practically
speaking, the use of short acting IC vasodilators such
as adenosine, ATP or papaverine is desirable, maximal
hyperemia can be achieved in a very short period of
time, and the measurements can be repeated within a
very short time interval. Recent studies by De Bruyne
et al.8 suggested that by providing sufficient dosage,
ATP, adenosine and papaverine are all able to induce
maximal hyperemia, but not contrast medium. IC ATP
or adenosine (20 to 40 ug) induces a similar degree of

Table 1. Comparison of four different pharmacological vasodilator agents
Intracoronary (IC) or
Intravenous (IV)
Dosage

Time to onset of
hyperemia
Duration of hyperemia
Pullback curve
Side effects

J HK Coll Cardiol, Vol 11

ATP
Both

Adenosine
Both

Papaverine
IC

Dobutamine
IV

IC: 15 to 20 ug for RCA
20 to 40 ug for LCA
IV:140-160 ug/kg/min
IC: 5 to 10s
IV:2 minutes
IC: 10s
IV:Infusion stop
IC: Impossible
IV:Possible
IC: Transient AV block
(Overdose).
IV:Decrease blood
pressure.
Increase heart rate.
Unpleasant angina
like burning sensation
in chest.

IC: 15 to 20 ug for RCA
20 to 40 ug for LCA
IV:140-160 ug/kg/min
IC: 5 to 10s
IV:2 minutes
IC: 10s
IV:Infusion stop
IC: Impossible
IV:Possible
IC: Transient AV block
(Overdose).
IV:Decrease blood
pressure.
Increase heart rate.
Unpleasant angina
like burning sensation
in chest.

IC: 15 mg for RCA
20 mg for LCA

IV: 20 ug/kg/min

IC: 30 to 60s

IV: 2 minutes

IC: Up to 2 minutes

IV:Infusion stop

IC: Possible

IV:Possible

IC: Polymorphic
ventricular
tachycardia,
ventricular
fibrillation,
and QTc
prolongation.

IV:Increase
heart rate.
Decrease
blood pressure.
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hyperemia as an IC bolus of 20 mg papaverine in human.
However, only IV ATP or adenosine and IC papaverine
are able to induce steady state hyperemia.

Adenosine
Adenosine is the most common pharmacological
vasodilator agent used for physiological assessments.
Several studies9,10 have shown that adenosine induces
maximal vasodilation in a very short period of time
(5 to 10 seconds), and the effect disappears within 30
sec. In addition, the magnitude of adenosine induced
hyperemia appears to be similar to that induced by
exercise-induced ischemia.11 Besides, compared with
papaverine, intravenous adenosine was found to be
equivalent in pharmacologic potency without significant
adverse side effects such as QTc prolongation.12,13
However, care must be taken during IC bolus
adenosine administration. One must inject very rapidly,
and flush the catheter with normal saline immediately
after the drug administration. It is because IC adenosine
bolus causes maximal hyperemia only for a short period
of time (less than 10s). Even though it is recommended
to use a dose of 15 to 20 ug in the right coronary artery
(RCA) and 18 to 24 ug in the left coronary artery
(LCA), 2,6 there is evidence suggesting that for some
patients higher doses may be needed to observe a better
hyperemic response.14,15

Papaverine
Papaverine used to be considered as the gold
standard for induction of maximum myocardial
hyperemia.19 A steady state hyperemia can be reached
within 30 to 60 seconds, and last for about 60 seconds
after IC bolus administration of 20 mg. However, the
use of this agent has been associated with some
serious clinical side effects, such as polymorphic
ventricular tachycardia,20 ventricular fibrillation21 and
QTc prolongation.12,13 In addition, studies have also
shown that IC infusion of papaverine induces a
significant increase in coronary venous plasma lactate
levels in patients with angiographically normal
coronary artery.22

Dobutamine
Studies on 22 patients with single vessel coronary
artery disease by Bartunek et al 23 showed that, IV
infusion of dobutamine at 20 ug/kg/min induced similar
degree of coronary hyperemia as adenosine, and higher
dose of IV infusion did not further affect the myocardial
resistance. However, up to present, there are only a few
experimental and clinical studies on the effect of this
agent on myocardial perfusion, studies on the feasibility
and safety of using this agent as a stimulus for
physiological assessment of a stenosis need to be further
explored.

ATP

Intravenous (IV) vs. Intracoronary (IC)

ATP has become a drug of choice recently, with
the potential advantage of lower cost, and lower rate of
side effect among the other common vasodilators used.
ATP is a precursor of adenosine, and therefore would
be expected to induce the same degree of coronary
hyperemia as adenosine. Since the half-life of ATP is
slightly longer than that of adenosine, it is commonly
believed that the hyperemic response might be
prolonged. ATP has been well established in human, it
has been shown to induce maximum hyperemia for CFR
(Coronary Flow Reserve) measurement16 and Thallium201 myocardial tomography. 17 Yamada et al18 have
reported that 50 ug of intracoronary ATP has similar
vasodilator potency as 10 mg papaverine and does not
produce any significant hemodynamic or electrocardiographic changes.

Generally speaking, IC bolus administration
offers more practical advantages than the IV infusion.
IC bolus administration is much easier and faster, and a
central venous access site is not needed. Only a small
fraction of the IV dosage is needed for IC bolus
administration, leading to significant reduction of cost.
For example, compared with IC adenosine (20-40 ug
for LCA; 15-20 ug for RCA), IV adenosine requires
relatively large doses (140 ug/kg/min) and is therefore
more costly. IC adenosine has an extremely rapid onset
of action, which makes it the ideal drug for repetitive
measurements. Jeremias et al24 examined differences
in FFR between IC and IV adenosine in 52 patients,
and the results showed IC adenosine is equivalent to IV
infusion for determination of FFR in large majority of
patients. However, in a small percentage of patients
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administered with IC adenosine, coronary hyperemia
was believed to be sub-optimal, and a repeated higher
IC adenosine may be needed. In addition, IV adenosine
is associated with more side effects than IC adenosine.
On the other hand, interruption of the aortic
pressure signals recording is needed for IC bolus
administration. Thus, it is very important to inject the
drug quickly and to flush with saline, after which the
aortic pressure should be immediately displayed. This
is especially important when IC ATP or adenosine is
used, the peak hyperemic period is only 5 to 10 seconds
long, and thus, a delay in obtaining the aortic pressure
may result in inaccurate pressure measurement. The use
of guiding catheters with side-holes should be avoided,25
and proper engagement of guiding catheter should be
ensured for preventing partial loss of the hyperemic drug,
otherwise the pressure measurements are unreliable.
Furthermore, IC bolus administration can only
determine the FFR at a single point in the arterial system.
For artery with multiple lesions, in order to evaluate
the physiological impact of each individual lesion on
the pressure drop, a pressure pullback curve26 can be
obtained by withdrawing the pressure guide wire very
slowly across the entire target artery. This curve
represents the pressure gradient over the entire length
of the artery and enables the registration of multiple
lesions in the presence of diffuse disease. For this
purpose a continuous maximal hyperemic condition is
necessary, and only IC papaverine and IV ATP or
adenosine induce complete, true steady state hyperemia
to enable a pressure pull back maneuver. Pullback
pressure recording during maximal hyperemia provides
a clear demonstration of the exact location and severity
of the stenosis.

FFR and Clinical Outcome
Diagnostic Applications
FFR is proven as a very useful diagnostic tool to
determine whether a stenosis, found at angiography, is
flow limiting and as a result is responsible for
myocardial ischemia. Studies on 45 patients with
moderate coronary stenosis and chest pain of uncertain
origin conducted by Pijls et al6 showed that, a FFR below
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0.75 is functionally significant and has been found to
correlate well with the presence of ischemia on
perfusion scintigraphy, stress echocardiography and
bicycle exercise testing, and that the specificity and
sensitivity of FFR are 100% and 88%.
Retrospective and prospective work from the
DEFER study (A randomized comparison of performance
versus deferral of angioplasty based upon coronary
pressure-derived fractional flow reserve) suggested that,
in patients with chest pain referred for angioplasty of
an intermediate stenosis, deferral of intervention in
patients with FFR exceeding 0.75 is safe and results in
an excellent clinical outcome.27

FFR guided PTCA
It has been shown a high FFR value after balloon
angioplasty is associated with a favorable long-term
outcome. Studies conducted by Bech et al28 showed that
long term clinical outcome after PTCA in patients with
both FFR of >0.90 and residual DS of <35% is excellent
and comparable with that event observed after coronary
stenting. In patients with post-PTCA FFR exceeding
0.90, the restenosis rate at 6, 12 and 24 months were
11%, 12% and 15% compared with 29%, 32% and 42%
in patients with post-PTCA FFR below 0.90 and a very
similar angiographic result. Therefore, even with an
angiographically excellent result, patients with a FFR
value below 0.90 still have a high event rate, and further
improvement may be achieved with coronary stent
implantation.

FFR and Stent Implantation
For a normal vessel, even during maximum
hyperemia, no pressure drop should be observed and
the value of FFR should be equal to 1.2 As a matter of
fact, after coronary stent implantation, the conductance
of the epicardial vessel should have normalized, and
the FFR should be close to its normal value. Thus, it is
suggested that FFR can also be used to evaluate the
result of stent placement.
One recent study29 showed that, post-stenting
FFR is a strong independent predictor of outcome at
6 months. For patients with post-stenting FFR exceeding
0.95, event rate is 4.9%; for post-stenting FFR between
0.90 and 0.95 event rate is 6.2%; for post-stenting FFR
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between 0.80 and 0.90, event rate is 20.3%; and for
post-stenting FFR below 0.80, event rate is 29.5%.
Another FFR after stenting study conducted by
Hanekamp et al30 further suggested that post-stenting
FFR exceeding 0.94 corresponds very well to
intravascular ultrasound (IVUS) results. Based on all
this evidence, it becomes a common practice to use FFR
to guide coronary stent placement. This research topic
also draws the attention of another research group from
the States. Studies by Fearon et al31 showed that, based
on validated IVUS criteria, post-stenting FFR below
0.96 predicts a suboptimal stent implantation result;
however, the result of this study also suggested that, an
post-stenting FFR exceeding 0.96 does not reliably
predict an optimal stenting result.
Even though whether post-stenting FFR is
reliable in evaluates optimal stent implantation is still a
controversial issue, it is commonly believed that, the
higher the value of post-stenting FFR, the better the
long term clinical outcome.

FFR and IVUS
Other than providing valuable information
regarding the morphology and distribution of coronary
plaques, IVUS may also help in assessing the functional
significance of a coronary stenosis. Takagi et al 32
demonstrated that IVUS minimal lumen area <3.0 mm2
and an area stenosis >60% had a potential to predict
FFR below 0.75. Recently, another comparing IVUS
and FFR study conducted by Briguori et al33 showed
that, an area stenosis >70%, minimal lumen diameter
of <1.8 mm, and a minimal lumen cross section area of
<4.0 mm2 were the best cutoff values for a FFR of below
0.75. Even though the IVUS thresholds of the two
studies were different, the results of the studies were
strongly supporting the idea that, there is a strong
correlation between the FFR and IVUS findings.

Discussion
Measurement of FFR with a pressure guide wire
is safe, rapid and efficient. However, this physiological
assessment technique is not routinely practiced in Hong
Kong or elsewhere. Three major concerns remain:
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1) FFR measurement requires additional expense for
the pressure guide wire and the interface box. 2) Welltrained operators and cathlab staff are needed, and the
learning curve is quite long and slow. 3) Performing
the pressure measurement procedure is time consuming,
because exchange of balloon catheters and/or further
stent deployment is needed to optimize results.
Generally speaking, time should not be a concern if the
cathlab staff are well trained, and the necessary
components are properly prepared, i.e. the pressure
console is well calibrated, cable connections are in good
order, the stimulus is ready to go, and extra pressure
guide wires are available in case of wire failure.
In conclusion, FFR is very useful in determining
whether or not a patient will benefit from a coronary
intervention. If a lesion is not physiological significant,
patients will not benefit from the procedure, and medical
treatment, which is safer and may eventually result in a
better outcome, should be used instead. Furthermore,
FFR measurement provides significant prognostic
benefit and improves the quality of the intervention.
As mentioned previously, a high FFR value after
angioplasty or stenting is associated with a favorable
long-term clinical outcome. Thus, even though the initial
treatment cost is high, this extra cost is offset by a better
long-term clinical outcome. Given the high cost of
intervention procedures, more research on the costeffectiveness of routine FFR guidance is needed.
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